Navigation Links
Celladon Corporation Announces Pre-clinical Study Demonstrating Inhalable MYDICAR Reverses Pulmonary Arterial Hypertension (PAH)
Date:7/30/2013

Janet C. Ross Professor of Medicine and Professor of Gene & Cell at Icahn School of Medicine at Mount Sinai. "We are excited about testing this therapy in PAH patients who are in critical need of intervention."

This same SERCA2a dysfunction also occurs in heart failure. This new study utilizes Celladon's product candidate MYDICAR which is currently under investigation in an international 200 patient Phase IIb trial in the United States and Europe. In 2012, Celladon and the Mt. Sinai School of Medicine entered into a license agreement granting Celladon certain exclusive worldwide rights to develop and commercialize SERCA2a gene therapy products for PAH.

"What we have shown is that gene therapy restores function of this crucial SERCA2a enzyme in diseased lungs," says Dr. Hajjar. "We are delighted with these new findings because it suggests that MYDICAR which is already showing great benefit in congestive heart failure patients may be able to help PAH patients who currently have no good treatment options — and are in critical need of a life sustaining therapy."

When SERCA2a is down-regulated, calcium stays longer in the cells than it should, and it induces pathways that lead to overgrowth of new and enlarged cells. According to researchers, the delivery of the SERCA2a gene through the MYDICAR product in turn produces SERCA2a enzymes, which helps both heart and lung cells restore their proper use of calcium.

"We are now on a path toward PAH patient clinical trials in the near future," says Dr. Hajjar, a co-founder of Celladon who developed the gene therapy approach. Studies in large animal models are now underway. SERCA2a gene therapy has already been approved by the National Institutes of Health for human study.

A Simple MYDICAR Inhalation Corrects Deadly Dysfunction
PAH most commonly results from heart failure in the left side of the heart or from a pulmonary embol
'/>"/>

SOURCE Celladon Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Celladon Corporation Named a 2012 Fierce 15 Company by FierceBiotech
2. Celladon Corporation To Present at BioCentury Future Leaders in the Biotech Industry Conference
3. Celladon Corporation and SIRO Clinpharm Announce Presentation at "Statisticians in the Pharmaceutical Industry International Conference"
4. Celladon Corporation Selected as Winner of Red Herrings "Top 100 North America Tech Startup"
5. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
6. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
7. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
8. Neogen Corporation Announces 2nd Quarter Results Conference Call
9. Luminex Corporation to Present at JP Morgan Healthcare Conference
10. Luminex Corporation Fourth Quarter and Full Year 2011 Earnings Release Scheduled for February 6, 2012
11. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... December 17, 2014 This report ... Quartz Tubing industry. For an overview analysis, the ... application, industry chain structure, industry overview, policy analysis, ... tubing industry has witnessed rapid development with ... of acquisitions. This report mentions quartz tubing upstream ...
(Date:12/17/2014)... Gene synthesis and bioengineering company ... into a technology access and services agreement with ... proprietary protein engineering technology, known as “ProteinGPS®” to ... extremely excited that the global leader ADM has ... bioengineering technology has now been validated through many ...
(Date:12/17/2014)... 2014  Vermillion, Inc. (NASDAQ: VRML ), ... announced the next step in its expanded strategy to ... with the naming of current Chief Operating Officer, ... while current Chairman of the Board and CEO ... These changes are effective January 1, 2015. ...
(Date:12/17/2014)... , Dec. 17, 2014 CASI Pharmaceuticals, Inc. ... to the acquisition, development and commercialization of innovative therapeutics ... global market with a primary commercial focus on ... been granted a Type C meeting with the U.S. ... will be held in February 2015.  During this meeting ...
Breaking Biology Technology:2020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5
... the Basque Country (Spain) has developed a method to ... and suspected to be explosive. Some of the samples ... and boric acid. Each year police forces seize ... indoor firework manufacturing (i.e. flares or those used in ...
... that affects about one in four military veterans of the ... which differed in importance depending upon the locations where veterans ... , Published online today in the journal ... and veterans, locations during the war. GWI was most ...
... recycling of "old" processes and protocols that were once ... settings, but which can now be applied to nano-sized ... instruments and know-how., After several years of research, scientists ... Emir Gonzlez (currently at Instituto Geofsico Universidad Javeriana y ...
Cached Biology Technology:Are those liquids explosive? 2Causes of Gulf War Illness are complex and vary by deployment area -- Baylor University study 2Causes of Gulf War Illness are complex and vary by deployment area -- Baylor University study 3
(Date:12/3/2014)... 2, 2014 As part of our commitment ... is pleased to announce the release of a new ... collect the workforce data that they need. ... left by existing readers. Many such devices have serious ... modern technology. Older models force users to navigate numerous ...
(Date:11/21/2014)... -- Earlier this year Donald Spector , Chairman of ... the most prolific inventors in the world, got a ... to third party agencies. Spector envisioned this technology even ... earliest known patents in this area. Now major technology ... care, elder care and hospital applications. This technology has ...
(Date:11/21/2014)... Wash. , Nov. 20, 2014 C-Labs ... for the Internet of Things (IoT), today announced the ... of chief operating officer. Previously a strategic advisor to ... finance, and operations. Mr. Traynor is based out of ... . He reports to Chris Muench , Chief ...
Breaking Biology News(10 mins):Inception Technologies to Release New Biometric Reader 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... COLLEGE STATION The U.S. Department of Energy has granted more ... fuel source. And if that succeeds within 18 months, almost $2 million ... fast-growing grass species. , ... our country is the leader around the world in terms of energy ...
... fishermen would not give up their livelihood in the face ... University of East Anglia (UEA). A new report, published ... about poverty and adaptation by investigating why fishermen in developing ... Daw from UEA,s School of International Development and the Stockholm ...
... 2012 Aware, Inc. (NASDAQ: AWRE ), a ... today reported financial results for its fourth quarter and year ... fourth quarter of 2011 was $5.9 million, a decrease of ... year. Net income for the fourth quarter of 2011 was ...
Cached Biology News:US Energy Department grants $1.87 million for plant fuel project 2University of East Anglia research reveals why fishermen keep fishing despite dwindling catches 2University of East Anglia research reveals why fishermen keep fishing despite dwindling catches 3Aware, Inc. Reports Fourth Quarter and 2011 Financial Results 2Aware, Inc. Reports Fourth Quarter and 2011 Financial Results 3Aware, Inc. Reports Fourth Quarter and 2011 Financial Results 4Aware, Inc. Reports Fourth Quarter and 2011 Financial Results 5
Mouse anti-JNK (PT183/185) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Acetyl CoA Carboxylase Antibody...
mu Opioid Receptor splice variant Immunogen: Synthetic peptide corresponding to residues K S C M D R G M R N L L P D D G P R Q E of Mu Opioid Receptor. Storage: -20 C, Avoid Freeze/Thaw Cycle...
Anti-BAR Immunogen: Peptide of aa 3-21 from human Bar Available Date: 38226...
Biology Products: